Phase 2 N=17 Discontinuation or Continuation of Immunosuppressive Therapy in Participants With Chronic Graft Versus Host Disease
Chronic Graft Versus Host Disease
Primary: Feasibility of Enrolling Patients — 21 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=27 Study of DS-8201a in Subjects With Advanced Solid Malignant Tumors
Advanced Solid Tumors
Primary: Objective Response Rate (ORR) Following Treatment With DS-8201a in Participants With Advanced Solid Malignant Tumors (Dose Escalation and Dose Expansion Phases) — 0…
Phase 2 N=123 A Double Blind, Randomized, Controlled Study to Evaluate CHF 5633 (Synthetic Surfactant) and Poractant Alfa in Neonates With Respiratory Distress Syndrome (RDS) (POC)
Respiratory Distress Syndrome, Newborn
Primary: Oxygen Requirement and Ventilatory Support -- SpO2/FiO2 Ratio — 3.33; 3.31; 3.36; 3.55 SpO2/FiO2 ratio — p=0.930
Phase 2 N=47 Lung-MAP: Talazoparib in Treating Patients With HRRD Positive Recurrent Stage IV Squamous Cell Lung Cancer
ATM Gene Mutation · ATR Gene Mutation · BARD1 Gene Mutation
Primary: Overall Response Rate Assessed by Response Evaluation Criteria in Solid Tumors 1.1 in HRRD-positive (MDVN) Participants — 4 percentage of participants
N/A N=349 A Trial of Rehabilitation Therapy in Older Acute Heart Failure Patients
Acute Decompensated Heart Failure
Primary: Short Physical Performance Battery (SPPB) at Month 3 — 6.9; 8.3 score on a scale — p=<0.0001
Phase 3 N=290 The Efficacy and Safety of Chlorhexidine Gluconate Chip (PerioChip®) in Therapy of Peri-implantitis
Peri-Implantitis
Primary: Absolute Change in Mean Probing Pocket Depth for Selected Target Implants — -1.69; -1.51 mm — p=0.1159
N/A N=52 Non-Inferiority Study of the FRESCA Airbox Positive Airway Pressure System
Sleep Apnea
Primary: Apnea-Hypopnea Index (AHI) — 3.20; 4.86 events/hr
Phase 2 N=53 Kanglaite Reduce the Toxicity of Radiotherapy of Head and Neck Cancer Phase II Study
Head and Neck Cancer · Radiotherapy
Primary: the Incidence Rate of Severe Radiation Mucositis — 3; 38; 5; 0 Participants
N/A N=103 Virtual Reality for Pain Management Study
Pain, Acute
Primary: Post-Treatment Pain Questionnaire — 3.03; 2.77; 6.37 score on a scale
Phase 3 N=645 Proxalutamide Treatment for Hospitalized COVID-19 Patients
Covid19 · SARS (Severe Acute Respiratory Syndrome)
Primary: 14 Day Recovery Rate — 258; 117 Participants
N/A N=620 Health Literacy Interventions to Overcome Disparities in CRC Screening
Colorectal Cancer
Primary: Initial CRC Screening — 213; 205 Participants — p=0.61
Phase 2 N=14 AGN-151597 (Formerly RST-001) Phase I/II Trial for Advanced Retinitis Pigmentosa
Advanced Retinitis Pigmentosa
Primary: Number of Participants With Any Grade 3 or Greater Adverse Event (AE) Considered Related to AGN-151597 — 0; 0; 0; 0 participants
Phase 2 N=30 A Study of Erwinaze Administered Intravenously in Patients Who Had an Allergy to Frontline Asparaginase Therapy
Acute Lymphoblastic Leukemia · Lymphoblastic Lymphoma
Primary: Two Day Nadir Serum Asparaginase Activity (NSAA) Level — 0.32 (IU/mL)
N/A N=37 Efficacy of 1540 Nanometer Erbium Glass Laser to Improve Benign Dermatofibromas
Dermatofibroma of Skin
Primary: Modified Patient and Observer Scar Assessment Scale Color Component Comparing Change From Baseline to Week 12. — -2.33 score on a scale
N/A N=15 Low Frequency Deep Brain Stimulation of the Subthalamic Nucleus in Parkinson's Disease
Parkinson Disease · Cognitive Impairment
Primary: Mean Reaction Time for Computerized Color Naming Stroop Task — 5.09 seconds